0.221
0.00 (1.33%)
| Previous Close | 0.218 |
| Open | 0.216 |
| Volume | 248,297 |
| Avg. Volume (3M) | 692,075 |
| Market Cap | 16,023,361 |
| Price / Book | 3.11 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.270 |
| Total Debt/Equity (MRQ) | 276.80% |
| Current Ratio (MRQ) | 0.290 |
| Operating Cash Flow (TTM) | -4.48 M |
| Levered Free Cash Flow (TTM) | -1.95 M |
| Return on Assets (TTM) | -151.41% |
| Return on Equity (TTM) | -1,544.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Klotho Neurosciences, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | -1.29 |
|
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 50.23% |
| % Held by Institutions | 2.60% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |